Jay Spiegel, MD

In this podcast, Drs. Dahiya and Spiegel discuss the FDA's 'Black Box' warning on CAR-T therapies for blood cancer patients. They explore the risks of secondary malignancies post-treatment and the impact of shifting CAR-T therapies to frontline treatments. The speakers stress the importance of informed consent, patient counseling, and evaluating the benefit-risk ratio in oncology treatments.